Epithalon vs NAD+
Verdict: Both live on the longevity shelf but bet on different biology. Epithalon is a synthetic pineal tetrapeptide from Russian research lines, associated with telomerase activation and circadian/melatonin normalization — run in short cycles a couple of times a year. NAD+ is a coenzyme your cells burn for repair and energy metabolism that declines with age; injections or infusions try to restore the pool directly, typically as an ongoing practice. Epithalon is the more speculative, lower-cost cycle; NAD+ has broader mainstream research interest but debate about whether injecting the raw molecule is the best way to raise it.
Side by side
| Epithalon | NAD+ | |
|---|---|---|
| Typical dose | 5 mg–10 mg | 50 mg–100 mg |
| Frequency | daily for 10–20 days, cycled 1–2x yearly | 1–3x weekly |
| Administration | subcutaneous injection | subcutaneous injection |
| Common vials | 10 mg, 20 mg, 50 mg | 100 mg, 500 mg, 1000 mg |
| Typical mix | 10 mg + 2 ml water | 500 mg + 5 ml water |
| Units for typical dose | 100 units (5 mg) | 50 units (50 mg) |
Mechanisms at opposite altitudes
Epithalon's proposed action is genomic: telomerase activation and pineal regulation, based largely on decades-old Russian animal and small human cohort studies that modern trials haven't replicated at scale. NAD+ is metabolic infrastructure — substrate for sirtuins and PARPs, central to DNA repair. Nobody disputes NAD+ matters; the argument is about delivery, since oral precursors (NMN/NR) and injections compete on how effectively they raise intracellular levels.
Protocol shape
Epithalon: classically 5–10 mg daily for 10–20 days, cycled 2× per year — a short pulse, not a habit. NAD+: 50–100 mg subcutaneous injections a few times weekly (with flushing/nausea limiting speed), or clinic infusions; benefits, when reported, fade without maintenance. One is a course, the other a subscription.
Evidence honesty
Neither has modern, large human RCTs for longevity endpoints. Epithalon's citations are old and geographically concentrated; NAD+ has abundant mechanistic science but thin clinical outcome data for injection protocols. Treat both as experiments, not therapies.
Can you stack them?
They don't overlap mechanistically, and longevity-focused users often run epithalon cycles on top of a continuous NAD+ practice. No known interaction — the constraint is budget and injection fatigue, not chemistry.
More comparisons
Educational comparison based on commonly published research protocols — not medical advice or an endorsement of any compound.